Both in Biotechnology
Recursion Pharmaceuticals vs Vericel
Over the past year RXRX returned −22.4% and VCEL returned +25.5%; their daily moves had a correlation of 0.29.
RXRX −22.4% VCEL +25.5%Growth of $1, one year, split-adjusted
| Metric | RXRX | VCEL |
|---|---|---|
| Price | $3.88 | $45.48 |
| Market cap | $2.32B | $2.33B |
| Today | +5.43% | +10.68% |
| 1 month | −16.2% | +13.6% |
| 6 months | +13.1% | +23.7% |
| Year to date | −5.1% | +26.3% |
| 1 year | −28.7% | +23.9% |
| Revenue growth (YoY) | +258.5% | +22.5% |
| Gross margin | 45.9% | 72.8% |
| Net margin | −641.6% | 2.8% |
| P/E (TTM) | — | 96.2× |
| Price / sales | 34.0× | 7.6× |
| Net cash | $538.0M | $162.5M |
| Dividend yield | — | — |
| Volatility (60d) | 95.9% | 38.8% |
| Short % of float | 37.5% | 11.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).